168 related articles for article (PubMed ID: 29988818)
1. Ocular Drug, Gene and Cellular Delivery Systems and Advanced Therapy Medicinal Products.
Eldem T; Eldem B
Turk J Ophthalmol; 2018 Jun; 48(3):132-141. PubMed ID: 29988818
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in ocular drug delivery.
Achouri D; Alhanout K; Piccerelle P; Andrieu V
Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
[TBL] [Abstract][Full Text] [Related]
3. [Nanoparticles as drug delivery systems in ophthalmology].
Löscher M; Hurst J; Strudel L; Spitzer MS; Schnichels S
Ophthalmologe; 2018 Mar; 115(3):184-189. PubMed ID: 29110121
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles as drug/gene delivery systems to the retina.
del Pozo-Rodríguez A; Delgado D; Gascón AR; Solinís MÁ
J Ocul Pharmacol Ther; 2013 Mar; 29(2):173-88. PubMed ID: 23286300
[TBL] [Abstract][Full Text] [Related]
5. Colloidal drug delivery system: amplify the ocular delivery.
Ali J; Fazil M; Qumbar M; Khan N; Ali A
Drug Deliv; 2016; 23(3):710-26. PubMed ID: 24892625
[TBL] [Abstract][Full Text] [Related]
6. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
[TBL] [Abstract][Full Text] [Related]
7. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.
Mandal A; Bisht R; Rupenthal ID; Mitra AK
J Control Release; 2017 Feb; 248():96-116. PubMed ID: 28087407
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology in ocular delivery: current and future directions.
Sultana Y; Maurya DP; Iqbal Z; Aqil M
Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
[TBL] [Abstract][Full Text] [Related]
9. Advanced drug delivery and targeting technologies for the ocular diseases.
Barar J; Aghanejad A; Fathi M; Omidi Y
Bioimpacts; 2016; 6(1):49-67. PubMed ID: 27340624
[TBL] [Abstract][Full Text] [Related]
10. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
11. Applications of nanoparticles in ophthalmology.
Diebold Y; Calonge M
Prog Retin Eye Res; 2010 Nov; 29(6):596-609. PubMed ID: 20826225
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery systems for the eye.
Kearns VR; Williams RL
Expert Rev Med Devices; 2009 May; 6(3):277-90. PubMed ID: 19419285
[TBL] [Abstract][Full Text] [Related]
13. Seeing the Future: A Review of Ocular Therapy.
Whalen M; Akula M; McNamee SM; DeAngelis MM; Haider NB
Bioengineering (Basel); 2024 Feb; 11(2):. PubMed ID: 38391665
[TBL] [Abstract][Full Text] [Related]
14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.
Souto EB; Doktorovova S; Gonzalez-Mira E; Egea MA; Garcia ML
Curr Eye Res; 2010 Jul; 35(7):537-52. PubMed ID: 20597640
[TBL] [Abstract][Full Text] [Related]
17. Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery.
Khiev D; Mohamed ZA; Vichare R; Paulson R; Bhatia S; Mohapatra S; Lobo GP; Valapala M; Kerur N; Passaglia CL; Mohapatra SS; Biswal MR
Nanomaterials (Basel); 2021 Jan; 11(1):. PubMed ID: 33445545
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():70-75. PubMed ID: 27789358
[TBL] [Abstract][Full Text] [Related]
19. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
20. Nanocarriers of nanotechnology in retinal diseases.
Al-Halafi AM
Saudi J Ophthalmol; 2014 Oct; 28(4):304-9. PubMed ID: 25473348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
